Evidence map›Paper›PMID 36163397›Full record

ArticleScientific reports2022

Upregulation of interleukin-19 in saliva of patients with COVID-19.

Fatemeh Saheb Sharif-Askari, Narjes Saheb Sharif-Askari, Shirin Hafezi, Swati Goel, Hawra Ali Hussain Alsayed, Abdul Wahid Ansari, Bassam Mahboub, Saleh Al-Muhsen, Mohamad-Hani Temsah, Qutayba Hamid and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Fatemeh Saheb Sharif-AskariSharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Narjes Saheb Sharif-AskariSharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Shirin HafeziSharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Swati GoelSharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Hawra Ali Hussain AlsayedPharmacy Department, Dubai Health Authority, Dubai, United Arab Emirates.
Abdul Wahid AnsariDermatology Institute, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
Bassam MahboubRashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates.
Saleh Al-MuhsenImmunology Research Laboratory, Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Mohamad-Hani TemsahImmunology Research Laboratory, Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Qutayba HamidSharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Rabih HalwaniSharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates. rhalwani@sharjah.ac.ae.
University of Sharjah · AEDubai Health Authority · AEKing Saud University · SAHamad Medical Corporation · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytokines are major players in orchestrating inflammation, disease pathogenesis and severity during COVID-19 disease. However, the role of IL-19 in COVID-19 pathogenesis remains elusive. Herein, through the analysis of transcriptomic datasets of SARS-CoV-2 infected lung cells, nasopharyngeal swabs, and lung autopsies of COVID-19 patients, we report that expression levels of IL-19 and its receptor, IL-20R2, were upregulated following SARS-CoV-2 infection. Of 202 adult COVID-19 patients, IL-19 protein level was significantly higher in blood and saliva of asymptomatic patients compared to healthy controls when adjusted for patients' demographics (P < 0.001). Interestingly, high saliva IL-19 level was also associated with COVID-19 severity (P < 0.0001), need for mechanical ventilation (P = 0.002), and/or death (P = 0.010) within 29 days of admission, after adjusting for patients' demographics, diabetes mellitus comorbidity, and COVID-19 serum markers of severity such as D-dimer, C-reactive protein, and ferritin. Moreover, patients who received interferon beta during their hospital stay had lower plasma IL-19 concentrations (24 pg mL

Indexed as

COVID-19AdultBiomarkersC-Reactive ProteinCytokinesFerritinsHumansInterferon-betaInterleukinsSalivaSARS-CoV-2Up-RegulationBiomarkersC-Reactive ProteinCytokinesFerritinsIL19 protein, humanInterferon-betaInterleukins

Identifiers

PMID36163397
PMCPMC9511465
OpenAlexW4297238887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.